Hippo pathway at the crossroads of stemness and therapeutic resistance in breast cancer
Molecular Oncology · 2026-07 · 20 (7) · 1667-1693
DOI: 10.1002/1878-0261.70232 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Molecular Oncology, online erschienen am 26.03.2026. Verfasst von Giulia Schiavoni und 11 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Trial Center, Biostatistics and Bioinformatics Unit, IRCCS Regina Elena National Cancer Institute, Rome, Italy. Hauptthemen laut MEDLINE: Neoplastic Stem Cells, Drug Resistance, Neoplasm, Protein Serine-Threonine Kinases, Breast Neoplasms. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 169 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Italian ministery of health, Fondazione AIRC per la ricerca sul cancro ETS.
Abstract (Originalsprache)
Breast cancer, the most frequently diagnosed cancer in women globally, is a heterogeneous disease with distinct subtypes requiring distinct therapeutic approaches. Regardless of molecular subtyping, breast cancer stem cells significantly contribute to tumor heterogeneity, distant dissemination, and therapeutic resistance. The Hippo pathway is a key regulator of organogenesis and tissue development, and its deregulation is common in breast cancer and linked to cancer stem cell features across several cancer types. Dysfunctional pathway activity leads to the aberrant activation of Hippo downstream effectors, the Yes‐associated protein (YAP) and its paralog transcriptional co‐activator with PDZ‐binding motif (TAZ), which promote epithelial‐to‐mesenchymal transition, growth factor‐independent proliferation, and maintenance of the breast cancer stem cells' niche. This review summarizes the regulation of the Hippo pathway, emphasizing its significant role in coordinating stemness‐related mechanisms in breast cancer. An overview of how the Hippo pathway fuels stemness in triple‐negative breast cancer, the most aggressive BC subtype, is then provided. We also discuss how the activation of stem cell‐like properties, driven by dysregulation of the Hippo pathway, contributes to the development of resistance to current therapies across the spectrum of breast cancer subtypes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Clinical Trial Center, Biostatistics and Bioinformatics Unit, IRCCS Regina Elena National Cancer Institute, Rome, Italy.
- Cellular and Molecular Biology, Department of Biology, University of Rome "Tor Vergata", Italy.
- Cellular Network and Molecular Therapeutic Target Unit, Department of Research, Diagnosis and Innovative Technologies, IRCCS Regina Elena National Cancer Institute, Rome, Italy.
- Department of Computer, Automatic and Management Engineering (DIAG), Sapienza University of Rome, Italy.
- Phase IV Studies, IRCCS Regina Elena National Cancer Institute, Rome, Italy.
- Oncogenomic and Epigenetic Unit, Department of Research, Diagnosis and Innovative Technologies, IRCCS Regina Elena National Cancer Institute, Rome, Italy.
ORCID-Profile: Giulia Bon
Förderung
- Italian ministery of health
- Fondazione AIRC per la ricerca sul cancro ETS
Zitieren
APA
Schiavoni, G., Palmese, A., Scalera, S., Cipriani, L., Mascolo, D., Vici, P., Arcuri, T., Filomeno, L., Krasniqi, E., Blandino, G., Bon, G., & Maugeri-Saccà, M. (2026). Hippo pathway at the crossroads of stemness and therapeutic resistance in breast cancer. Molecular Oncology, 20(7), 1667-1693. https://doi.org/10.1002/1878-0261.70232
Vancouver
Schiavoni G, Palmese A, Scalera S, Cipriani L, Mascolo D, Vici P, et al. Hippo pathway at the crossroads of stemness and therapeutic resistance in breast cancer. Molecular Oncology. 2026;20(7):1667-1693. doi:10.1002/1878-0261.70232
BibTeX
@article{Schiavoni2026,
author = {Schiavoni, Giulia and Palmese, Antonella and Scalera, Stefano and Cipriani, Laura and Mascolo, Davide and Vici, Patrizia and Arcuri, Teresa and Filomeno, Lorena and Krasniqi, Eriseld and Blandino, Giovanni and Bon, Giulia and Maugeri-Saccà, Marcello},
title = {Hippo pathway at the crossroads of stemness and therapeutic resistance in breast cancer},
journal = {Molecular Oncology},
year = {2026},
volume = {20},
number = {7},
pages = {1667--1693},
doi = {10.1002/1878-0261.70232}
}
EUVIMED